Myeloproliferative Disorders-Research Consortium
12
0
0
8
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 65/100
25.0%
3 terminated/withdrawn out of 12 trials
72.7%
-13.8% vs industry average
8%
1 trials in Phase 3/4
50%
4 of 8 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
Polycythemia Vera, Myelofibrosis and Essential Thrombocythemia: Identification of PV, MF & ET Genes
Role: collaborator
Research Tissue Bank
Role: collaborator
Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)
Role: collaborator
Ruxolitinib Prior to Transplant in Patients With Myelofibrosis
Role: collaborator
Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AML
Role: collaborator
Correlative Biomarker Study in Patients With Myeloproliferative Disorders
Role: collaborator
Familial Myeloproliferative Disorders
Role: collaborator
Study of Fludarabine Based Conditioning for Allogeneic Stem Cell Transplantation for Myelofibrosis
Role: collaborator
Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET)
Role: collaborator
Clopidogrel and Aspirin for the Treatment of Polycythemia Vera
Role: collaborator
CEP-701 (Lestaurtinib) in Myelofibrosis
Role: collaborator
Phase II Study of Bevacizumab (Avastin®) in Myelofibrosis
Role: collaborator
All 12 trials loaded